Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring study of intravenous norvancomycin in hospitalized patients
ChiCTR2000039794Phase 4Recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Nov 2020
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of norvancomycin in Gram-positive bacterial infection, sepsis, Central nervous system infection and 4 more, sponsored by The Second Hospital of Hebei Medical University. Primary endpoints: Liver function and Renal function. Started Nov 2020; status: recruiting.
02
Drugs
norvancomycin
03
Conditions
Gram-positive bacterial infectionsepsisCentral nervous system infectionpneumonialung abscess
Beyond the preview
Go deeper on ChiCTR2000039794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039794.